MARC details
| 000 -LEADER |
|---|
| fixed length control field |
05536nam a2200541 i 4500 |
| 001 - CONTROL NUMBER |
|---|
| control field |
EBC3379240 |
| 003 - CONTROL NUMBER IDENTIFIER |
|---|
| control field |
MiAaPQ |
| 006 - FIXED-LENGTH DATA ELEMENTS--ADDITIONAL MATERIAL CHARACTERISTICS |
|---|
| fixed length control field |
m o d | |
| 007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION |
|---|
| fixed length control field |
cr cnu|||||||| |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
130605t20122012dcua ob 100 0 eng|d |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
|---|
| Canceled/invalid ISBN |
9780309260244 |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
|---|
| Canceled/invalid ISBN |
0309260248 |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
|---|
| Canceled/invalid ISBN |
9780309260213 |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
|---|
| International Standard Book Number |
9780309260251 (e-book) |
| 035 ## - SYSTEM CONTROL NUMBER |
|---|
| System control number |
(MiAaPQ)EBC3379240 |
| 035 ## - SYSTEM CONTROL NUMBER |
|---|
| System control number |
(Au-PeEL)EBL3379240 |
| 035 ## - SYSTEM CONTROL NUMBER |
|---|
| System control number |
(CaPaEBR)ebr10863895 |
| 035 ## - SYSTEM CONTROL NUMBER |
|---|
| System control number |
(OCoLC)817900348 |
| 040 ## - CATALOGING SOURCE |
|---|
| Original cataloging agency |
MiAaPQ |
| Language of cataloging |
eng |
| Description conventions |
rda |
| -- |
pn |
| Transcribing agency |
MiAaPQ |
| Modifying agency |
MiAaPQ |
| 043 ## - GEOGRAPHIC AREA CODE |
|---|
| Geographic area code |
n-us--- |
| 050 #4 - LIBRARY OF CONGRESS CALL NUMBER |
|---|
| Classification number |
RS420 |
| Item number |
.G4 2012 |
| 082 0# - DEWEY DECIMAL CLASSIFICATION NUMBER |
|---|
| Classification number |
615.1 |
| Edition number |
23 |
| 245 00 - TITLE STATEMENT |
|---|
| Title |
Genome-based therapeutics : |
| Remainder of title |
targeted drug discovery and development : workshop summary / |
| Statement of responsibility, etc. |
Adam C. Berger and Steve Olson, Rapporteurs ; Roundtable on Translating Genomic-Based Research for Health, Board on Health Sciences Policy, Institute of Medicine of the National Academies. |
| Medium |
[electronic resource] |
| 246 30 - VARYING FORM OF TITLE |
|---|
| Title proper/short title |
Targeted drug discovery and development |
| 264 #1 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE |
|---|
| Place of production, publication, distribution, manufacture |
Washington, District of Columbia : |
| Name of producer, publisher, distributor, manufacturer |
National Academies Press, |
| Date of production, publication, distribution, manufacture, or copyright notice |
[2012] |
| 264 #4 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE |
|---|
| Date of production, publication, distribution, manufacture, or copyright notice |
©2012 |
| 300 ## - PHYSICAL DESCRIPTION |
|---|
| Extent |
1 online resource (109 pages) : |
| Other physical details |
illustrations |
| 504 ## - BIBLIOGRAPHY, ETC. NOTE |
|---|
| Bibliography, etc. note |
Includes bibliographical references (pages 55-57). |
| 505 0# - FORMATTED CONTENTS NOTE |
|---|
| Formatted contents note |
Introduction -- The current landscape -- Case studies: The development of Crizotinib for treatment of non-small-cell lung cancer; Use of genetics to inform drug development for the treatment of schizophrenia; A genetic approach to the treatment of cystic fibrosis -- Emerging technologies in drug development: Large-scale whole-genome sequencing; The value of clinical next-generation sequencing to drug developers; The uses of genomic information -- Evolving paradigms: Foundations and drug development: an example; Genomics and regulatory science; Pharmacy benefit management and pharmacogenomics; Repurposing of drugs -- Forging collaborative strategies for the development of personalized medicine: The need for collaboration; FDA initiatives; NCATS initiatives; Biospecimens and databases; Reducing health disparities; Patient and physican education; An emphasis on the science. |
| 520 ## - SUMMARY, ETC. |
|---|
| Summary, etc. |
"The number of new drug approvals has remained reasonably steady for the past 50 years at around 20 to 30 per year, while at the same time the total spending on health-related research and development has tripled since 1990. There are many suspected causes for this trend, including increases in regulatory barriers, the rising costs of scientific inquiry, a decrease in research and development efficiency, the downstream effects of patient expirations on investment, and the lack of production models that have successfully incorporated new technology. Regardless, this trajectory is not economically sustainable for the businesses involved, and, in response, many companies are turning toward collaborative models of drug development, whether with other industrial firms, academia, or government. Introducing greater efficiency and knowledge into these new models and aligning incentives among participants may help to reverse the trends highlighted above, while producing more effective drugs in the process. Genome-based therapeutics explains that new technologies have the potential to open up avenues of development and to identify new drug targets to pursue. Specifically, improved validation of gene-disease associations through genomics research has the potential to revolutionize drug production and lower development costs. Genetic information has helped developers by increasing their understanding of the mechanisms of disease as well as individual patients' reactions to their medications. There is a need to identify the success factors for the various models that are being developed, whether they are industry-led, academia-led, or collaborations between the two. Genome-Based Therapeutics summarizes a workshop that was held on March 21, 2012, titled New paradigms in drug discovery: how genomic data are being used to revolutionize the drug discovery and development process. At this workshop the goal was to examine the general approaches being used to apply successes achieved so far, and the challenges ahead"--Publisher's description. |
| 588 ## - SOURCE OF DESCRIPTION NOTE |
|---|
| Source of description note |
Description based on print version record. |
| 590 ## - LOCAL NOTE (RLIN) |
|---|
| Local note |
Electronic reproduction. Ann Arbor, MI : ProQuest, 2015. Available via World Wide Web. Access may be limited to ProQuest affiliated libraries. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Drugs |
| Geographic subdivision |
United States |
| General subdivision |
Design |
| Form subdivision |
Congresses. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Pharmaceutical technology |
| Geographic subdivision |
United States |
| Form subdivision |
Congresses. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Pharmaceutical industry |
| Geographic subdivision |
United States |
| Form subdivision |
Congresses. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Genomics |
| Geographic subdivision |
United States |
| Form subdivision |
Congresses. |
| 655 #4 - INDEX TERM--GENRE/FORM |
|---|
| Genre/form data or focus term |
Electronic books. |
| 9 (RLIN) |
18 |
| 700 1# - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Berger, Adam C., |
| Relator term |
contributor. |
| 700 1# - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Olson, Steve, |
| Dates associated with a name |
1956- |
| Relator term |
contributor. |
| 710 2# - ADDED ENTRY--CORPORATE NAME |
|---|
| Corporate name or jurisdiction name as entry element |
Institute of Medicine (U.S.). |
| Subordinate unit |
Roundtable on Translating Genomic-Based Research for Health, |
| Relator term |
issuing body. |
| 710 2# - ADDED ENTRY--CORPORATE NAME |
|---|
| Corporate name or jurisdiction name as entry element |
Institute of Medicine (U.S.). |
| Subordinate unit |
Board on Health Sciences Policy, |
| Relator term |
issuing body. |
| 776 08 - ADDITIONAL PHYSICAL FORM ENTRY |
|---|
| Relationship information |
Print version: |
| Title |
Genome-based therapeutics : targeted drug discovery and development : workshop summary. |
| Place, publisher, and date of publication |
Washington, District of Columbia : National Academies Press, [2012] |
| Physical description |
xx, 89 pages ; 23 cm. |
| International Standard Book Number |
9780309260213 |
| Record control number |
(OCoLC)ocn824457733 |
| -- |
(DLC) 2012554410 |
| 797 2# - LOCAL ADDED ENTRY--CORPORATE NAME (RLIN) |
|---|
| Corporate name or jurisdiction name as entry element |
ProQuest (Firm) |
| 856 40 - ELECTRONIC LOCATION AND ACCESS |
|---|
| Uniform Resource Identifier |
<a href="http://ebookcentral.proquest.com/lib/aitie/detail.action?docID=3379240">http://ebookcentral.proquest.com/lib/aitie/detail.action?docID=3379240</a> |
| Public note |
Click to View |